Advisory services to the biomedical industry with a focus on general management and business development strategy and transactions as well as FDA regulatory strategies and execution.

Strategy development for a start-up company with a platform technology in biosurgical adhesives and re-purposed therapeutics for GU indications. Building an effective organization to implement aggressive business plan which includes topical adhesives, internal surgical adhesive/sealant, drug delivery of adhesive biospheres and consumer and industrial markets.Identify and negotiate strategic alliances and raise funding for enterprise.

• Developed worldwide growth strategy, identified licensing opportunities in the US and closed three major platform technology deals (peak year revenue estimates for these deals exceed $500 million)• Developed growth strategy for building sales and market presence of enterprise • Opened negotiations with existing and new potential business partners for major additional business development transactions

Led business transactions and served on senior management team to provide corporate leadership

Rejoined Johnson & Johnson and assumed responsibility for licensing and acquisition, initially for Ethicon Products and subsequently for J&J Wound Management business units:• Identified new market and technology platforms, executed key partnerships, licenses and acquisitions, and led process improvement efforts (which accelerated capital-efficient profitable growth) and the 12-person due diligence team • As Member of Advanced Wound Care and Surgical Wound Care Leadership Teams, assisted in development of JJWM growth strategy as well as Internal Adhesive strategy• Managed business development portion of the integration of J&J Medical into Ethicon• During tenure with Ethicon, personally closed the majority of transactions: in 2002, seven transactions with peak year sales potential exceeding $150 million (received Johnson & Johnson Achievement Award); in 2003, three major transactions with market potential exceeding $300 million

Member of Company Management Board reporting to President. Developed the regulatory affairs function and obtained strategic new contact lens approvals including Acuvue Disposable Contact Lens